Myriad Genetics, Inc. (MYGN) Tops Q4 EPS by 1c; Guides FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.82 +1.04%
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.01 better than the analyst estimate of $0.29. Revenue for the quarter came in at $107.4 million versus the consensus estimate of $104.43 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- World Acceptance (WRLD) Tops Q2 EPS by 113c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
